HOME >> BIOLOGY >> NEWS
Chromosome deletion predicts aggressive neuroblastoma

When genes are deleted on a particular section of chromosome 11, the result is an aggressive form of the childhood cancer neuroblastoma. A new study suggests that detecting this genetic deletion during the initial evaluation of children with neuroblastoma may indicate to physicians that they should recommend a more aggressive regimen of chemotherapy to fight the cancer.

Edward F. Attiyeh, M.D., a pediatric oncology fellow at The Children's Hospital of Philadelphia, reported on a study of 915 patients in a presentation today at the American Society of Clinical Oncology annual meeting in Orlando, Fla. The patients were children with primary neuroblastoma treated at Children's Oncology Group (COG) centers. The COG is a National Institutes of Health-funded multicenter clinical research organization that supports clinical trials for pediatric cancer patients.

Neuroblastoma, which accounts for 10 percent of all pediatric cancers, often occurs as a solid tumor in a child's abdomen or chest. Some cases of neuroblastoma are low risk, and resolve after surgeons remove the tumor. Other cases are more aggressive, and are more likely to resist initial treatment, or to cause a relapse. Identifying the correct risk level allows doctors to treat aggressive cancers appropriately, while not subjecting children with low-risk cancer to overtreatment.

Oncologists know that amplification, an abnormal increase in the number of copies, of a cancer-causing gene called MYCN heralds a high-risk, aggressive cancer. However, a significant number of neuroblastomas are aggressive without having amplified MYCN. "The deletion of genetic material on chromosome 11 may account for a significant percentage of these high-risk neuroblastomas," said Dr. Attiyeh.

It is unknown what causes the deletion of genes on chromosome 11, at a location designated chromosome 11q23. However, the loss of material at that site apparently removes the protective effect of a tumor suppress
'"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
16-May-2005


Page: 1 2

Related biology news :

1. Chromosome glue repairs damaged DNA
2. Chromosome rearrangements not as random as believed
3. Chromosome regions containing genes related to alcohol addiction affect drinking behavior in smokers
4. Chromosome four contains genes that affect drinking behaviors in smokers
5. Chromosome 16 publication fulfills DOEs human genome commitment
6. Teens with deletion syndrome confirm genes role in psychosis
7. Gene predicts better outcome as cortex normalizes in teens with ADHD
8. Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds
9. Major study predicts grim future for Europes seas
10. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
11. NASA predicts nongreen plants on other planets

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/1/2018)... Ariz. (PRWEB) , ... July 31, 2018 , ... ... Father of Stevia Awards at Global Conference , Awards honor late founder of ... president of Wisdom National Brands, presented prestigious stevia awards to a renowned German ...
(Date:7/31/2018)... ... July 31, 2018 , ... ACEA Biosciences, is a privately owned biotechnology ... just introduced the xCELLigence RTCA S16, which the ideal entry level model for exploratory ... the S16can be placed in any standard CO2 tissue culture incubator. The user ...
(Date:7/31/2018)... ... , ... Fiberstar, Inc. , a global leader of clean label, functional ... years, Fiberstar added capacity, introduced new Citri-Fi® products and entered into new categories. To ... up with Batory Foods. , “Batory Foods has an excellent track record within ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... 2018 , ... John McDonald, CEO of ClearObject , ... India Business Council (IIBC), an advocacy group to strengthen economic ties between Indiana ... McDonald joins an impressive roster of local and national business leaders from organizations ...
(Date:7/24/2018)... ... July 24, 2018 , ... R3 Stem Cell is now offering regenerative therapies ... offered by Double Board Certified providers, with outcomes significantly improving patient quality of life. ... have done nothing to help repair and regenerate damaged lung tissues. Stem cell ...
(Date:7/24/2018)... ... July 24, 2018 , ... ... of their highly successful SmartTRAK platform. Not just a pretty face, SmartTRAK ... and speed. , SmartTRAK is the world’s first online and real-time data ...
(Date:7/22/2018)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology ... program in Dry Eye Disease. Under the agreement Essex Bio-Investment will fund U.S. ... first Phase 3 study starting as early as Fall 2018. , “We ...
Breaking Biology Technology:
Cached News: